Abstract:

Objective　To investigate the effect of tofacitib combined with eramode for patients with rheumatoid arthritis and the effect on their cellular immune function. Methods　A total of 102 patients with rheumatoid arthritis admitted to Jincheng People's Hospital from January 2020 to December 2022 were selected and divided into a combined group and a conventional group by random number table method, with 51 case in each group. The conventional group took eramode, and the combined group took eramode and tofacitib, for 3 months. The clinical efficacies, inflammatory response [interleukin (IL) -10 and IL-12], cellular immune function [immunoglobin G (IgG) ], and adverse reactions were compared between the two groups. χ² and t tests were applied. Results　After the treatment, the total effective rate of the combined group was higher than that of the conventional group [94.12% (48/51) vs. 78.43% (40/51)], with a statistical difference between the two groups (P<0.05). After the treatment, the levels of IL-10 and IL-12 in the combined group were lower than those in the conventional group [(31.34±4.97) ng/L vs. (39.42±5.12) ng/L and (3.28±0.51) ng/L vs. (6.59±0.91) ng/L; both P<0.05]. After the treatment, the levels of CD3+ and CD19+ cells in the combined group were higher than those in the conventional group [(66.78±6.45)% vs. (55.12±5.28)% and (88.76±12.45)% vs. (65.67±10.11)%; both P<0.05]. After the treatment, the serum IgG level in the combined group was lower than that in the conventional group [(10.23±1.24) g/L vs. (14.78±2.32) g/L; P<0.05]. There was no statistical difference in the total incidence of adverse reactions between the two groups [9.80% (5/51) vs. 7.84% (4/51); P>0.05]. Conclusion　Tofacitib and eramode for patients with rheumatoid arthritis is significantly effective and safe and can reduce their inflammatory response and improve cellular immune function, so it worthy of clinical promotion and application.

Key words:

Rheumatoid arthritis, Tofacitib, Eramode, Cellular immune function, Adverse reactions

摘要：

目的　探讨托法替布联合艾拉莫德应用于类风湿关节炎的效果及对细胞免疫功能的影响。方法　选取2020年1月至2022年12月晋城市人民医院收治的102例类风湿关节炎患者，以随机数字表法将其分为联合组（51例）与常规组（51例）。常规组采用艾拉莫德治疗，联合组采用托法替布联合艾拉莫德治疗，两组治疗时间均为3个月。对比两组临床疗效、炎性反应［白细胞介素（IL）-10、IL-12］、细胞免疫功能［血清免疫球蛋白G（IgG）］水平及不良反应情况。采用χ²检验、t检验进行统计分析。结果　治疗后，联合组总有效率为94.12%（48/51），常规组为78.43%（40/51），两组比较差异有统计学意义（P<0.05）。治疗后，联合组血清IL-10、IL-12分别为（31.34±4.97）ng/L、（3.28±0.51）ng/L，常规组分别为（39.42±5.12）ng/L、（6.59±0.91）ng/L，联合组均低于常规组（均P<0.05）。治疗后，联合组CD3+、CD19+细胞水平分别为（66.78±6.45）%、（88.76±12.45）%，常规组分别为（55.12±5.28）%、（65.67±10.11）%，联合组均高于常规组（均P<0.05）；治疗后，联合组血清IgG水平（10.23±1.24）g/L，常规组为（14.78±2.32）g/L，联合组低于常规组（P<0.05）。两组不良反应总发生率比较［9.80%（5/51）比7.84%（4/51）］，差异无统计学意义（P>0.05）。结论　托法替布联合艾拉莫德治疗类风湿关节炎患者效果显著，能降低患者的炎性反应水平，有利于改善细胞免疫功能，且安全，值得推广与应用。

关键词:

类风湿关节炎, 托法替布, 艾拉莫德, 细胞免疫功能, 不良反应